Epidemiology, pathophysiology, prognosis, and treatment of systolic and diastolic heart failure in elderly patients

Heart Disease

Volumn 5, Issue 4, 2003, Pages 279-294

  Aronow, Wilbert S ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

blockers; Angiotensin converting enzyme inhibitors; Digoxin; Diuretics; Heart failure

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; FUROSEMIDE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; METOPROLOL; NESIRITIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OMAPATRILAT; PERINDOPRIL; QUINAPRIL; RAMIPRIL; SPIRONOLACTONE; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN;

AGE DISTRIBUTION; ALCOHOL CONSUMPTION; ANEMIA; ANGIONEUROTIC EDEMA; ARTIFICIAL HEART PACEMAKER; BRADYCARDIA; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY DISEASE; COUGHING; DEHYDRATION; DIASTOLE; DIGITALIS INTOXICATION; DISEASE CLASSIFICATION; DRUG CONTRAINDICATION; DRUG INDICATION; EXERCISE; FEVER; FLUID INTAKE; FOLLOW UP; GERONTOLOGY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEART REHABILITATION; HEART SURGERY; HEART VENTRICLE ARRHYTHMIA; HUMAN; HUMIDITY; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; HYPOXIA; INFECTION; INOTROPISM; KIDNEY FAILURE; LUNG EMBOLISM; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PROGNOSIS; QUALITY OF LIFE; RASH; REVIEW; RISK FACTOR; SEX RATIO; SIDE EFFECT; SODIUM INTAKE; SYSTOLE; TACHYCARDIA; TASTE DISORDER; THYROID DISEASE; UREMIA;

AGE DISTRIBUTION; AGED; CARDIAC OUTPUT, LOW; DIASTOLE; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SEX DISTRIBUTION; SURVIVAL RATE; SYSTOLE; UNITED STATES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0041402686     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hdx.0000080714.87750.48     Document Type: Review

References (122)

1. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Developed in collaboration with the International Society for Heart and Lung Transplantation. Endorsed by the Heart Failure Society of America. J Am Coll Cardiol. 2001;38: 2101-2113.
2. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J. 1991;121:951-957.
3. O'Connell JB, Bristow MR. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant. 1994;13:S107-S112.
4. Aronow WS, Ahn C, Kronzon I, Koenigsberg M. Congestive heart failure, coronary events and atherothrombotic brain infarction in elderly blacks and whites with systemic hypertension and with and without echocardiographic and electrocardiographic evidence of left ventricular hypertrophy. Am J Cardiol. 1991;67:295-299.
5. Aronow WS, Ahn C, Kronzon I. Comparison of incidences of congestive heart failure in older African-Americans, Hispanics, and whites. Am J Cardiol. 1999;84:611-612.
6. Aronow WS. Effects of aging on the heart. In: Tallis RC, Fillit HM, Brocklehurst JC, eds. Brocklehurst's Textbook of Geriatric Medicine and Gerontology, 5th ed. Edinburgh: Churchill Livingstone; 1998:255-262.
7. Aronow WS. Left ventricular diastolic heart failure with normal left ventricular systolic function in older persons. J Lab Clin Med. 2001; 137:316-323.
8. Lakatta EG, Yin FCP. Myocardial aging: functional alterations and related cellular mechanisms. Am J Physiol. 1982;242:H927-H941.
9. Wei JY, Spurgeon HA, Lakatta EG. Excitation-contraction in rat myocardium: alterations with adult aging. Am J Physiol. 1984;246: H784-H791.
10. Morgan JP, Morgan KG. Calcium and cardiovascular function: intracellular calcium levels during contraction and relaxation of mammalian cardiac and vascular smooth muscle as detected with aequorin. Am J Med. 1984;77(suppl 5A):33-46.
11. Bandy B, Davison AJ. Mitochondrial mutations may increase oxidative stress: implications for carcinogenesis and aging? Free Radic Biol Med. 1990;8:523-539.
12. Corral-Debrinski M, Stepien G, Shoffner JM, et al. Hypoxemia is associated with mitochondrial DNA damage and gene induction: implications for cardiac disease. JAMA. 1991;266:1812-1816.
13. Olivetti G, Melissari M, Capasso JM, Anversa P. Cardiomyopathy of the aging human heart. Myocyte loss and reactive cellular hypertrophy. Circ Res. 1991;68:1560-1568.
14. Lie JT, Hammond PI. Pathology of the senescent heart: anatomic observation on 237 autopsy studies of patients 90 to 105 years old. Mayo Clin Proc. 1988;63:552-554.
15. Schaub MC. The aging of collagen in the heart muscle. Gerontologia. 1964;10:38-41.
16. Verzar F. The stages and consequences of aging collagen. Gerontologia. 1969;15:233-239.
17. Hachamovitch R, Wicker P, Capasso JM, Anversa P. Alterations of coronary blood flow and reserve with aging in Fischer 344 rats. Am J Physiol. 1989;256:H66-H73.
18. Aronow WS, Ouslander JG. Heart disease in the aged. In: Branch WT, Alexander W, Schlant R, eds. Cardiology in Primary Care Practice. New York: McGraw-Hill; 2000:807-834
19. Ogawa T, Spina R, Martin WH III, et al. Effects of aging, sex and physical training on cardiovascular responses to exercise. Circulation. 1992;86:494-503.
20. Manning WJ, Shannon RP, Santinga JA, et al. Reversal of changes in left ventricular diastolic filling associated with normal aging using diltiazem. Am J Cardiol. 1989;67:894-896.
21. Kitzman BW, Higginbotham MB, Cobb FR, et al. Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the Frank-Starling mechanism. J Am Coll Cardiol. 1991;17:1065-1072.
22. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
23. Aronow WS, Ahn C, Gutstein H. Prevalence of atrial fibrillation and association of atrial fibrillation with prior and new thromboembolic stroke in elderly patients. J Ant Geriatr Soc. 1996;44:521-523.
24. Wong WF, Gold S, Fukuyama O, Blanchette PL. Diastolic dysfunction in elderly patients with congestive heart failure. Am J Cardiol. 1989; 63:1526-1528.
25. Aronow WS, Ahn C, Kronzon I. Prognosis of congestive heart failure in elderly patients with normal versus abnormal left ventricular systolic function associated with coronary artery disease. Am J Cardiol. 1990; 66:1257-1259.
26. Pemenkil R, Vinson JM, Shah AS, et al. Course and prognosis in patients ≥70 years of age with congestive heart failure and normal versus abnormal left ventricular ejection fraction. Am J Cardiol. 1997; 79:216-219.
27. Aronow WS, Ahn C, Kronzon I. Normal left ventricular ejection fraction in older persons with congestive heart failure. Chest. 1998; 113:867-869.
28. Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction. J Am Coll Cardiol. 1999;33:1948-1955.
29. Gottdiener JS, McClelland RL, Marshall R, et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med. 2002;137: 631-639.
30. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823.
31. Aronow WS, Ahn C, Kronzon I. Prognosis of congestive heart failure after prior myocardial infarction in older men and women with abnormal versus normal left ventricular ejection fraction. Am J Cardiol. 2000;85:1382-1384.
32. Aronow WS, Ahn C, Kronzon I. Prognosis of congestive heart failure after prior myocardial infarction in older persons with atrial fibrillation versus sinus rhythm. Am J Cardiol. 2001;87:224-225.
33. Aronow WS, Tresch DD, Nanna M. Aortic valve disease in the elderly. In: Tresch DD, Aronow WS, eds. Cardiovascular Disease in the Elderly Patient, 2nd ed. New York: Marcel Dekker; 1999;345-370.
34. Aronow WS, Ahn C, Kronzon I, Nanna M. Prognosis of congestive heart failure in patients aged ≥62 years with unoperated severe valvular aortic stenosis. Am J Cardiol. 1993;72:846-848.
35. Aronow WS, Ahn C, Kronzon I, Nanna M. Prognosis of patients with heart failure and unoperated severe aortic valvular regurgitation and relation to ejection fraction. Am J Cardiol. 1994;74:286-288.
36. Aronow WS. Exercise therapy for older persons with cardiovascular disease. Am J Geriatr Cardiol. 2001;10:245-252.
37. Weber KT, Brilla C. Pathologic hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991; 83:1849-1865.
38. The CONSENSUS Trial Study Group. Effect of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
39. Cohn J, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303-310.
40. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
41. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-828.
42. Garg R, Yusuf for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 1995;273:1450-1456.
43. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 1992;327:669-677.
44. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691.
45. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;333:1670-1676.
46. Aronow WS, Ahn C, Kronzon I. Effect of beta blockers alone, of angiotensin-converting enzyme inhibitors alone, and of beta blockers plus angiotensin-converting enzyme inhibitors on new coronary events and on congestive heart failure in older persons with healed myocardial infarcts and asymptomatic left ventricular systolic dysfunction. Am J Cardiol. 2001;88:1298-1300.
47. Aronow WS, Kronzon I. Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am J Cardiol. 1993;71:602-604.
48. Philbin EF, Rocco TA Jr, Lindenmuth NW, et al. Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. Am J Med. 2000;109:605-613.
49. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999;100:2312-2318.
50. Dries DL, Strong MH, Cooper RS, Drazner MH. Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptordatic left ventricular dysfunction to symptomatic heart failure in black and white patients. J Am Coll Cardiol. 2002;40:311-317.
51. Vanhoutte PM, Auch-schwelk W, Biondi ML, et al. Why are converting enzyme inhibitors vasodilators? Br J Clin Pharmacol. 1989;28: 95S-104S.
52. Weksler BB, Pett SB, Alonso D, et al. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med. 1983;308:800-805.
53. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol. 1994;20:1549-1555.
54. Boger RH, Bodeboger SM, Kramme P, et al. Effect of captopril on prostacyclin and nitric oxide formation in healthy human subjects: interaction with low dose acetylsalicylic acid. Br J Clin Pharmacol. 1996;42:721-727.
55. Evans MA, Burnett JC Jr, Redfield MM. Effect of low dose aspirin on cardiorenal function and acute hemodynamic response to enalaprilat in a canine model of severe heart failure. J Am Coll Cardiol. 1995;25: 1445-1450.
56. Katz SD, Radin M, Graves T, et al. Effect of aspirin and ifetroban on skeletal muscle blood flow in patients with congestive heart failure treated with enalapril. J Am Coll Cardiol. 1999;34:170-176.
57. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol. 1997;79:115-119.
58. Al-Khadra AS, Salem DN, Rand WM, et al. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol. 1998;31:419-425.
59. Leor J, Reicher-Reiss H, Goldbourt U, et al. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors. A cohort study of 11,575 patients with coronary artery disease. J Am Coll Cardiol. 1999;33:1920-1925.
60. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet. 2000;355:1575-1581.
61. Chen Y-T, Radford MJ, Krumholz HM. Aspirin and the treatment of heart failure in the elderly (abstract). J Am Coll Cardiol. 2000;35:541A.
62. Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med. 1993;153:937-942.
63. Jilma B, Krejcy K, Dirnberger E, et al. Effects of angiotensin-II infusion at pressor and subpressor doses on endothelin-1 plasma levels in healthy men. Life Sci. 1997;60:1859-1866.
64. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
65. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004-1010.
66. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582-1587.
67. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.
68. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA. 1982; 247:1707-1714.
69. Pedersen TR for the Norwegian Multicentre Study Group. Six-year follow-up of the Norwegian Multicentre Study on Timolol after acute myocardial infarction. N Engl J Med. 1985;313:1055-1058.
70. Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation. 1986;73:503-510.
71. Kennedy HL, Brooks MM, Barker AH, et al. Beta-blocker therapy in the Cardiac Arrhythmia Suppression Trial. Am J Cardiol. 1994;74: 674-680.
72. Aronow WS, Ahn C, Mercando AD, Epstein S, Kronzon I. Effect of propranolol versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in patients ≥62 years of age with heart disease, complex ventricular arrhythmias, and left ventricular ejection fraction ≥40%. Am J Cardiol. 1994;74:267-270.
73. Aronow WS, Ahn C. Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and diabetes mellitus. Am J Cardiol. 2001;87:780-781.
74. Aronow WS, Ahn C. Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and symptomatic peripheral arterial disease. Am J Cardiol. 2001;87:1284-1286.
75. Furberg CD, Hawkins CM, Lichstein E, for the Beta-Blocker Heart Attack Trial Study Group. Effect of propranolol in postinfarction patients with mechanical or electrical complications. Circulation. 1984; 69:761-765.
76. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-1355.
77. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353: 9-13.
78. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2007.
79. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in chronic heart failure. N Engl J Med. 2001;344:651-658.
80. Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction ≥40% treated with diuretics plus angiotensin-converting-enzyme inhibitors. Am J Cardiol. 1997;80:207-209.
81. Mann DL, Deswal A, Bozkurt B, Torre-Amione G. New therapeutics for chronic heart failure. Ann Rev Med. 2002;53:59-74.
82. Ohtsuka T, Hamada M, Hiasa G, et al. Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2001;37: 412-417.
83. Wiklund O, Hulthe J, Wikstrand J, et al. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke. 2002;33:572-577.
84. Moye L, Pfeifer M, for the SAVE Investigators. Additional beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. J Am Coll Cardiol. 1997;29:229-236.
85. Exner DV, Dries DL, Waclawiw MA, et al. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1999;33:916-923.
86. Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology: W. J. Remme and K. Swedberg (Co-Chairmen). Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001;22:1527-1560.
87. Aronow WS. Echocardiography should be performed in all elderly patients with congestive heart failure. J Am Geriatr Soc. 1994;42: 1300-1302.
88. Tresch DD, McGough MF. Heart failure with normal systolic function: a common disorder in older people. J Am Geriatr Soc. 1995;43:1035-1042.
89. Lorell BH, Isoyama S, Grice WN, et al. Effects of oubain and isoproterenol on left ventricular diastolic function during low-flow ischemia in isolated blood perfused rabbit hearts. Circ Res. 1988;63: 457-467.
90. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J. Med. 1997;336: 525-533.
91. Rich MW, McSherry F, Williford WO, et al. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG Study. J Am Coll Cardiol. 2001;38:806-813.
92. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Eng J Med. 2002;347:1403-1411.
93. Aronow WS. Digoxin or angiotensin converting enzyme inhibitors for congestive heart failure in geriatric patients. Which is the preferred treatment? Drugs Aging. 1991;1:98-103.
94. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
95. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314:1547-1552.
96. Cohn JN, Johnson G, Veterans Administration Cooperative Study Group. Heart failure with normal ejection fraction. The V-HeFT Study. Circulation. 1990;81(suppl III):III-53.
97. Packer M, Califf RM, Konstan MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure. The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002;106:920-926.
98. Abraham WT, Ascheim D, Demarco T, et al. Effects of enrasentan, a nonselective endothelin receptor antagonist in class II to III heart failure: results of the Enrasentan Cooperative Randomized (ENCOR) Evaluation. J Am Coll Cardiol. 2001;38:612.
99. McMurray J, Pfeffer MA. New therapeutic options in congestive heart failure. Part II. Circulation. 2002;105:2223-2228.
100. Elkayam U, Amin J, Mehra A, et al. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation. 1990;82:1954-1961.
101. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1988;319:385-392.
102. Goldstein RE, Boccuzzi SJ, Cruess D, et al. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation. 1991;83:52-60.
103. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 1996;335:1107-1114.
104. Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril. V-HeFT III. Circulation. 1997;96:856-863.
105. Setaro JF, Zaret BL, Schulman DS, et al. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol. 1990;66:981-986.
106. Causa S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med. 2001;344:873-880.
107. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845-1853.
108. Linde C, Leclercq C, Rex S, et al. Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in Cardiomyopathy (MUSTIC) Study. J Am Coll Cardiol. 2002; 40:111-118.
109. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 1991;325:1468-1475.
110. Packer M, Rouleau J, Swedberg K, et al. Effect of flosequinan on survival in chronic heart failure: preliminary results of the PROFILE study (abstract). Circulation. 1993;88(suppl I):I-301.
111. Uretsky BF, Jessup F, Konstan MA, et al. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Circulation. 1990;82:774-780.
112. Cohn JN, Goldstein SO, Greenberg BH, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med. 1998;339:1810-1816.
113. Pimobendan in Congestive Heart Failure (PICO) Investigators. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) Trial. Heart. 1996;76:223-231.
114. Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet. 1990;336:1-6.
115. Hampton JR, Van Veldhusisen DJ, Kleber FX, et al. Randomized study of effect of ibopamine on survival in patients with advanced heart failure. Lancet. 1997;349:971-977.
116. O'Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 2000;138:78-86.
117. Rich MW, Woods WL, Davila-Roman VG, et al. A randomized comparison of intravenous amrinone versus dobutamine in older patients with decompensated congestive heart failure. J Am Geriatr Soc. 1995;43:271-274.
118. Dries F, Krell MJ, Whitlow P, et al. Intermittent dobutamine in ambulatory out-patients with chronic cardiac failure (abstract). Circulation. 1986;74(suppl II):II-38.
119. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure. A randomized controlled trial. JAMA. 2002;287:1531-1540.
120. Silver MA, Horton DP, Ghali JK, Elkayam U. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol. 2002;39:798-803.
121. Athanasuleas CL, Stanley AW Jr., Buckberg GD, et al. Surgical anterior ventricular endocardial restoration (SAVER) in the dilated remodeled ventricle after anterior myocardial infarction. RESTORE group. Reconstructive Endoventricular Surgery, returning Torsion Original Radius Elliptical Shape to the LV. J Am Coll Cardiol. 2001;37:1210-1213.
122. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345:1435-1443.